<DOC>
	<DOCNO>NCT00284817</DOCNO>
	<brief_summary>- Assess safety tolerance weekly MEDI522 regimen patient irinotecan-refractory advanced CRC solid tumor refractory standard therapy .</brief_summary>
	<brief_title>Phase I Study MEDI522 Patients With Irinotecan-Refractory Advanced Colorectal Cancer</brief_title>
	<detailed_description>- Assess safety tolerance weekly MEDI 522 regimen patient irinotecan-refractory advanced CRC . - Determine Phase II recommend dose base acceptable dose-limiting toxicity . Other consideration pharmacokinetic parameter may also factor determination Phase II dose . The secondary objective study : - Assess antitumor activity MEDI-522 patient population .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>Patients must histologicallyconfirmed advanced CRC progress irinotecancontaining regimen metastatic disease , recur , within 6 month complete , irinotecancontaining adjuvant regimen , histologicallyconfirmed solid tumor refractory standard therapy . Age least 18 year time first dose study drug . Both male female eligible . Sexually active female , unless surgically sterile ( least one year postmenopausal ) , must use effective method avoid pregnancy ( include oral implanted contraceptive , IUD , female condom , diaphragm spermicide , cervical cap , abstinence , use condom sexual partner sterile sexual partner ) 30 day prior first dose study drug , must agree continue use precaution 30 day final dose study drug . Sexually active female reproductive potential must negative serum b human chorionic gonadotropin ( bhCG ) pregnancy test within 3 day start therapy . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . ECOG criterion describe Appendix A . Patients prior treatment chemotherapy radiotherapy prior surgery eligible study entry least 4 week past since treatment/surgery . All toxicity relate prior treatment must resolve surgical wound must heal . Prior immunotherapy approve agent allowable . ANC ³1500/mm3 , platelet ³100,000/mm3 , hemoglobin &gt; 10.0 g/dL , serum creatinine £1.5 mg/dL calculate creatinine clearance &gt; 50 mL/min , serum bilirubin £2.0 mg/dL , AST/ALT £5 time upper limit normal ( ULN ) . PT/PTT le ULN international normalize ratio ( INR ) less 1.12 . Thyroxine ( T4 ) thyroidstimulating hormone ( TSH ) within normal limit . Written inform consent obtain patient prior receipt study medication begin study procedure . Pregnancy nursing . Known brain metastasis primary brain tumor , symptomatic pleural effusion ascites require paracentesis . Respiratory insufficiency require oxygen treatment , lymphangitic involvement lung . Any evidence hematemesis , melena , hematochezia , gross hematuria . A history significant adverse event relate previously administer humanize monoclonal antibody . A known human immunodeficiency virus ( HIV ) hepatitis virus infection . A prior myocardial infarction angina , uncontrolled hypertension ( systolic blood pressure &gt; 150 mm Hg ) . A prior stroke transient ischemic attack . An active infection require systemic antiinfective therapy . Received investigational agent last 4 week initiation study treatment . A requirement palliative chemotherapy , hormonal therapy , immunotherapy course study . Clinical evidence bowel obstruction . A history malignancy within past 5 year ( exception basal cell carcinoma skin completely excise situ carcinoma cervix ) . A general medical psychological condition behavior , include substance dependence abuse , opinion investigator , might permit patient complete study sign inform consent . Prior treatment MEDI522 MEDI523 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
</DOC>